The ACL will produce and characterize fit-for-purpose affinity reagents based on the individual requestor’s specifications. These reagents will be produced and characterized using validated methods, ensuring the NIH Rigor and Reproducibility Principles and Guidelines are followed. A key focus of this project will be to continue to make good quality, well characterized affinity reagents for the scientific community, while exploring alternative methodologies for reagent production and characterization. Approximately, 75 – 150 targets per target application cycle is anticipated. The range is based on an array of costs associated with various production and characterization methods, and thus the number of targets will be defined by a cap in dollar amount and not target number. In target request cycles where more full length, unmodified targets are selected, traditional mouse monoclonal antibodies will be favored, thus allowing for a higher number of targets to be selected due to the lower costs of monoclonal mouse antibodies. Conversely, when the selected targets include peptides, specifically those intended for targeted proteomic assays such as Immuno-MRM (iMRM) applications, and/or those which target specific PTMs, then rabbit monoclonal antibodies would be favored at a higher cost, resulting in a lower number of targets selected. The target prioritization will be determined by the NCI’s Antibody Scientific Committee which will review all target requests within a given application cycle for ranking. The depth of the target list will depend on the type of affinity reagent that will be required based on the target type (protein, peptide, modification) and the intended use. All successful affinity reagents will be deposited at Developmental Studies Hybridoma Bank (DSHB) for research use only and all data will be added to the NCI’s antibody portal. The PCL will develop and implement standardized proteomic measurements (comprehensive and targeted) for pre-clinical research and clinical trials. The PCL will utilize, whenever possible, NCI’s affinity reagents (either previously produced/characterized or developed for a project) for targeted proteomic measurements. It is anticipated that this Task Order will complement work done within the existing severable and non-severable task orders (75N91021F00010). It is anticipated that 100 rabbit monoclonal antibodies will be needed to support PCL targeted proteomics. The ACL will also analyze all final antibodies for potential use beyond iMRM. When appropriate the antibodies will be sent to DSHB and added to the antibody portal. In addition to the ACL and PCL activities, this Task Order will support comprehensive proteomic data generation with PTMs and metabolomics (if appropriate) for different cancer types in support of CPTAC proteomic pipeline projects. In the base period it is anticipated that 500 samples (NCI to provide) will require comprehensive proteomic data generation with PTMs, assume phospho, ubiqui...